The drug, previously known as BOL-303259-X and NCX 116 is a nitric oxide-donating prostaglandin F2 alpha analog, for which Bausch paid the French company an initial $10 million in March 2010, according to a release. Results from Phase 2b testing in 2011 were positive, so Bausch paid Nicox another $10 million to pursue further testing in a Phase 3’s two separate randomized, multicenter, double-masked, parallel-group studies, according to the release.
Nicox could earn as much as $162.5 million from Bausch if the product goes to market, and would receive tiered double-digit royalties from sales and be able to co-promote the product in the U.S.
More Articles on Ophthalmology:
50 Statistics on ASC Net Revenue by Specialty
10 Milestones for Ambulatory Surgery Centers
3 Reasons LASIK Surgery is More Popular in the Winter
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
